← 返回

H2AFY2 通过转录和表观遗传修饰抑制耗竭并增强 CAR-T 细胞的抗肿瘤活性

英文原题:H2AFY2 suppresses exhaustion and enhances antitumor activity of CAR-T cells through transcriptional and epigenetic modifications.

查看英文原题

H2AFY2 suppresses exhaustion and enhances antitumor activity of CAR-T cells through transcriptional and epigenetic modifications.

PubMed 2026/08/11(内容时间) Cancer Immunol Res Q1 · IF 7.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

嵌合抗原受体(CAR)-T细胞耗竭是持续抗肿瘤疗效的关键障碍。通过对淋巴瘤患者CAR-T 细胞的转录组分析,我们鉴定出组蛋白变体macroH2A2(H2AFY2)是T细胞耗竭的关键调控因子——这一发现在多种肿瘤模型中均得到一致观察。在小鼠中,T细胞特异性敲除H2afy2通过激活核因子κB通路并增加Rela基因座的染色质可及性,促进抑制性受体的表达,这一点已通过单细胞RNA测序和转座酶可及性染色质测序得以证实。CD8+ T细胞中H2AFY2过表达诱导显著的表观遗传重塑,其特征为H3K27me3富集增加。在机制上,Rela基因座的H3K27me3富集抑制p65介导的转录激活,导致耗竭相关转录因子TOX下调,从而改善T细胞耗竭。

此外,过表达H2AFY2的CAR-T 细胞维持较低水平的抑制性受体并抑制肿瘤复发。总体而言,这些结果界定了一条表观遗传通路,H2AFY2通过该通路对抗T细胞耗竭,并支持H2AFY2工程化CAR-T 细胞跨肿瘤类型的治疗潜力。

展开英文摘要原文

Chimeric antigen receptor (CAR)-T cell exhaustion constitutes a critical barrier to sustained antitumor efficacy. Through transcriptomic analysis of CAR-T cells from patients with lymphoma, we identified the histone variant macroH2A2 (H2AFY2) as a critical regulator of T cell exhaustion-a finding consistently observed across multiple tumor models.

In mice, T cell-specific knockout of H2afy2 promots the expression of inhibitory receptors by activating the nuclear factor kappa-B pathway and increasing chromatin accessibility at the Rela locus, as demonstrated by single-cell RNA-sequencing and assay for transposase-accessible chromatin sequencing. H2AFY2 overexpression in CD8+ T cells induces prominent epigenetic remodeling, characterized by increased H3K27me3 enrichment.

Mechanistically, H3K27me3 enrichment at the Rela locus suppresses p65-mediated transcriptional activation, leading to downregulation of the exhaustion-associated transcription factor TOX and consequent amelioration of T cell exhaustion.

Furthermore, H2AFY2-overexpressing CAR-T cells sustain lower levels of inhibitory receptors and suppressed tumor recurrence. Collectively, these results define an epigenetic pathway through which H2AFY2 counteracts T cell exhaustion and support the therapeutic potential of H2AFY2-engineered CAR-T cells across tumor types.

论文信息

作者
Li C、Wang Q、Zhao Q、Cai Q、Wang S、Ping Y、Zhao X、Chen X
单位
First Affiliated Hospital of Zhengzhou University Zhengzhou, Henan China.China
期刊
Cancer immunology research2026 Aug 11
原文标识
PubMed 42578983 · DOI 10.1158/2326-6066.CIR-25-1334